Monitoring public health impact of HPV vaccination on RRP

Abstract

Recurrent respiratory papillomatosis (RRP) is a rare disease resulting from human papillomavirus (HPV) infection. Estimates of disease burden may vary due to non-standardized study methodology. Monitoring of RRP can characterize RRP burden, identify risk factors and susceptible populations, detect rare complications, identify opportunities for prevention, and evaluate current therapies and public health interventions. Since the 2006 introduction of HPV vaccine in the United States, monitoring may be useful for measuring vaccine impact on reducing or preventing RRP. RRP monitoring may also help identify opportunities to improve quality of life for active cases and reduce overall costs associated with disease management. Potential methods for monitoring RRP include national surveillance systems, nationally representative health surveys, registries and collaboratives, and administrative claims databases. Ideally, a national RRP registry or database may enable assessment of HPV vaccine impact on RRP burden in countries with HPV vaccination programs.